Providence’s Katherine R. Tuttle, MD, FASN, explains why semaglutide is preferred in T2D and CKD and how guidelines sequence added therapies.
Katherine R. Tuttle, MD, FASN
Advertisement
Articles by Katherine R. Tuttle, MD, FASN
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
3
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
4
Dialysis Access, Church CKD Screening Address Kidney Care Inequities
5